Clinical trial
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin: a Randomized, Open, Parallel Study
NCT00384215 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin: a Randomized, Open, Parallel Study
- Lead sponsor
- Sanofi
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 31, 2001
- Completion date
- February 28, 2005
- Enrollment
- 352
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.